v3.26.3
Intangible Asset, Net (Details) - USD ($)
$ in Thousands
6 Months Ended
Aug. 13, 2024
Jun. 30, 2026
Jun. 30, 2025
Intangible Asset, Net [Line Items]      
Achievement of milestones $ 3,320    
Product basis rate   5.00%  
Proceedings of equity   $ 5,000  
Percentage of sublicenses   25.00%  
Intangible asset impairment loss    
Amortization expense for intangible assets   $ 150 $ 150
License [Member]      
Intangible Asset, Net [Line Items]      
Estimate useful life   10 years  
Pre-Funded Warrants [Member]      
Intangible Asset, Net [Line Items]      
Warrants issued upon IPO (in Shares)   243  
Warrants [Member]      
Intangible Asset, Net [Line Items]      
Warrants issued upon IPO (in Shares)   1,369  
SciSparc [Member] | Ordinary Shares [Member]      
Intangible Asset, Net [Line Items]      
Ordinary shares issued (in Shares)   213  
License Agreement [Member]      
Intangible Asset, Net [Line Items]      
Fair value of shares committed to be issued   $ 3,000  
Preclinical safety test [Member]      
Intangible Asset, Net [Line Items]      
Achievement of milestones 50,000    
Phase I Clinical Trial [Member]      
Intangible Asset, Net [Line Items]      
Achievement of milestones 100,000    
Phase 2a Clinical Trial [Member]      
Intangible Asset, Net [Line Items]      
Achievement of milestones 120,000    
Phase 2b Clinical Trial [Member]      
Intangible Asset, Net [Line Items]      
Achievement of milestones 150,000    
Phase 3 Clinical Trials [Member]      
Intangible Asset, Net [Line Items]      
Achievement of milestones 500,000    
FDA [Member]      
Intangible Asset, Net [Line Items]      
Achievement of milestones 800,000    
EU Regulatory Body [Member]      
Intangible Asset, Net [Line Items]      
Achievement of milestones 800,000    
Additional Jurisdiction Clinical [Member]      
Intangible Asset, Net [Line Items]      
Achievement of milestones $ 800,000    
IPO [Member]      
Intangible Asset, Net [Line Items]      
Issued initial public offering   $ 3,000